A half-century of neurotransmitter research: Impact on neurology and psychiatry

Bioscience Reports

Volumn 21, Issue 6, 2001, Pages 691-710

  Carlsson, Arvid ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Bain; Dopamine; Neurotransmitter; Serotonin

Indexed keywords

3 [3 (METHYLSULFONYL)PHENYL] 1 PROPYLPIPERIDINE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; BRAIN MONOAMINE; CHLORPROMAZINE; DEXAMPHETAMINE; DIPHENHYDRAMINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; FLUOXETINE; HALOPERIDOL; LEVODOPA; NEUROLEPTIC AGENT; NEUROTRANSMITTER; NORADRENALIN; PHENIRAMINE; PRECLAMOL; RESERPINE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; ZIMELDINE;

ANIMAL EXPERIMENT; BRAIN; CONFERENCE PAPER; CONTROLLED STUDY; DEPRESSION; DOPAMINERGIC SYSTEM; DYSKINESIA; EXPERIMENTAL MODEL; HISTORY OF MEDICINE; HUMAN; HUNTINGTON CHOREA; MEDICAL RESEARCH; MENTAL DISEASE; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROPHARMACOLOGY; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PSYCHOPHARMACOLOGY; PSYCHOSIS; RABBIT; RAT; SCHIZOPHRENIA; SEROTONINERGIC SYSTEM; SIDE EFFECT;

ANIMALS; AUTOBIOGRAPHY; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; NEUROLOGY; NEUROTRANSMITTER AGENTS; PORTRAITS; PSYCHIATRY; SWEDEN;

ANIMALIA; ORYCTOLAGUS CUNICULUS;

EID: 0035780532     PISSN: 01448463     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1015556204669     Document Type: Conference Paper

References (50)

1. Andén N.-E., Carlsson A., and Häggendal, J.(1969) Adrenergic mechanisms. Ann. Rev. Pharmacol. 9:119-134.
2. Andén N.-E., et al. (1970) Oral L-DOPA treatment of Parkinsonism. Acta Med. Scand. 187:247-255.
3. Barbeau, A., Sourkes, T. L., and Murphy, G. F. (1962) Les catecholamines dans la maladie de Parkinson. In: Monoamines et Système Nedrveux Central. Génève, Georg et Cie, S.A., pp. 247-262.
4. Berntsson, P. B., Carlsson, P. A. E., and Corrodi, H. R. (1972) Belg. Pat. 781105 (72-4-14).
5. Bertler, Å. and Rosengren, E. (1959) Occurrence and distribution of dopamine in brain and other tissues. Experientia 15:10.
6. Birkmayer, W. and Hornykiewicz, O. (1961) Der L-3,4-dioxyphenylalanin ( = L-DOPA)-effekt bei der Parkinson-Akinese. Wien Klin. Wschr. 73:787-788.
7. Carlsson, A. (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11:490-493
8. Carlsson, A. (1960) Zur frage der wirkungsweise einiger psychopharmaka. Psychiat. Neurol. 140:220-222.
9. Carlsson, A. (1966) Physiological and pharmacological release of monoamines in the central nervous system. In: Mechanisms of Release of Biogenic Amines (U. S. von Euler, S. Rosell, and B. Uvnäs, eds.), Pergamon Press, Oxford, pp. 331-346.
10. Carlsson, A. (1998) Autobiography. In: The History of Neuroscience in Autobiography, Volume 2 (L. R. Squire, ed.), Academic Press, San Diego, pp. 28-66.
11. Carlsson, A. (1999) The discovery of the SSRIs: A milestone in neuropsychopharmacology and rational drug design. In: Selective Serotonin Reuptake Inhibitors (S. C. Stanford, ed.), R. G. Landes Company, Austin, pp. 1-8.
12. Carlsson, A. and Hillarp, N.-Å. (1956) Release of adrenaline from the adrenal medullaof rabbits produced by reserpine. Kungl. Fysiogr. Sällsk. i Lund. Förhandl. 26:8.
13. Carlsson. A. and Lindqvist, M. (1963) Effect of chlorpromazine or haloperidol on the formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol. (Kbh) 20:140-144.
14. Carlsson, A. and Lindqvist, M. (1969) Central and periphgeral monoaminergic membrane-pump blockade by some addictive analgesics and antihistamines. J. Pharm. Pharmac. 21:460-464.
15. Carlsson, A. and Waldeck, B. (1958) A fluorimetric method for the determination of dopamine (3-hydroxytyramine). Acta Physiol. Scand. 44:293-298.
16. Carlsson, A., Rosengren, E., Bertler Å., and Nilsson, J. (1957a) Effect of the resorpine on the metabolism of cathecolamines. In: Psychotropic Drugs (S. Garattini and V. Ghetti, eds.), Elsevier, Amsterdam, pp. 363-372.
17. Carlsson, A., Lindqvist, M., and Magnusson, T. (1957b) 3,4-Dihydroxyphenylalanine and 5-hydroxytrytophan as reserpine autagonists. Nature 180:1200.
18. Carlsson, A., Lindqvist, M., Magnusson, T. and Waldock, B. (1958 On the presence of 3-hydroxytyramine in brain. Science 127:471.
19. Carlsson, A., Falck, B., Hillarp, N.-Å., Thicme, G. and Torp, A. A new histochemical method for visualization of tissue catecholamines. Med. Exp. 4:123-125.
20. Carlsson, A., Fuxe, K., Ungerarcdi, U. (1968) The effect of imipramine on central 5-hydroxytrypiamine neurons. J. Pharm. Pharmacol. 20:150-151.
21. Carlsson, A., Gottfries, C.-G., Holmberg, G., Modigh, K., Svensson, T. H., and Ögren, S.-O. (eds.) (1981) Recent advances in the treatment of depression. Acta Physiol. Scand. Suppl. 290.
22. Carlsson, A., Waters, N., Waters, S., and Carlsson, M. L. (2000) Network interactions in schizophreniutherapeutic implications. Brain. Res. Rev. 31:342-349.
23. Colzias, G. C., Van Woerr, M. H. and Schitler, L. M. (1767) Aromatic amino acids and modification of Parkinsonism. New Eng. J. Med. 276:374-379.
24. Dahlstrom, A. and Carlsson, A. (1986) Making visible the invisible. (Recollections of the first experiences with the histochemical flourescene method for visualization of tissue monoamines). In: Discoveries in Pharmacology, Vol. 3 (M. J. Paruham and J. Bruinvels. eds.), Elsevier, Amsterdam/New York/Oxford, pp. 97-128.
25. 6. Klin. Wschr. 38: 120-123.
26. Ehringer, H. and Hornykiewicz, O. (1960) Verteilung von noradrenalin und dopamin (3-hydroxytyramin) im gehirn des menschen und ihr verhalten bei erkrankungen des extrapyramidalen sytstems. Klin. Wschr. 38:1236-1239.
27. Ekesbo, A. (1999) Functional Consequences of Dopaminergic Degeneration. Thesis, Uppsala University, pp. 1-59.
28. Euler, U. S. von and Hamberg, U. (1949) Colorimetric determination of noradrenaline and adrenaline. Acta Physiol. Scand. 19:74-84.
29. Euler, U. S. von, Rosell, S., and Uvnäs, B. (eds.) (1966) Mechanisms of Release of Biogenic Amines. Pergamon Press, Oxford, pp. 331-346.
30. Falck, B., Hillarp, N.-Å., Thieme, G., and Torp, A. (1962) Fluorescence of catecholamines and related compounds condensed with formaldehyde. J. Histochem. Cytochem. 10:348-354.
31. Foley, P. (2000) The L-DOPA story, revisited. Further surprises to be expected? The contribution of Isamo Sano to the investigation of Parkinson's disease. In: Advances in Research on Neurodegeneration, Volume 8 (P. Riederer, D. B. Calne, R. Horowski, Y. Mizuno, C. V. Olanow, W. Poewe, M. B. H. Youdim, eds.), Springer-Verlag, Vienna, pp. 1-20.
32. Gefvert, O. et al. (2000) (-)-OSU6162 induces a rapid onset of antipsychotic effect after a single dose. A double-blind placebo-controlled study. Abstract. Nordic. J. Psychiat. 54:93-94.
33. Girolami, P., Taborikova, H., Nistico, G. (eds.) (1994) In Memory of Sir Henry Dale. Accademia di Scienze Mediche e Biologiche, Rome, pp. 1-67.
34. Hornykiewicz, O. (1966) Metabolism of brain dopamine in human Parkisonism: Neurochemical and clinical aspects. In: Biochemistry and Pharmacology of the Basal Ganglia (E. Costa. L. K. J. Côté, and M. D. Yahr, eds.), Raven Press. New York, pp. 171-186.
35. Hornykiewicz, O. (1992) From dopamine to Parkinson's disease: A personal research record. In: The Neurosciences: Paths of Discovery II (F. Samson and G. Adelman, eds.) Birkhäuser, Boston, pp. 125-148.
36. Isacsson, G. (2000). Suicide prevention - A medical breakthrough? Acta Psychiat. Scand. 102:113-117.
37. Kanigel, R. (1986) Apprentice to Genius, The Making of a Scientific Dynasty. Macmillan, New York, pp. 1-271.
38. Katz B. (1996) In: The History of Neuroscience in Autobiography. Volume 1 (L. R. Squire, ed.), Society for Neuroscience, Washington, pp. 348-381.
39. Kramer, P. D. (1993) Listening to Prozac, Penguin Books, New York.
40. Lahti, A. C., Weiler, M. A., Corey, P. K., Lahti, R., A., Carlsson, A., and Tamminga, C. A. Antipsychotic properties of the partial dopamine agonist(-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in schizophrenia. Biol Psychiat. 43:2-11.
41. Loewi, O. (1921) Über humorale überträgberkeit der herznervenwirkung. (I. Mitteilung). Pflüg. Arch. Ges Physiol. 189:239-242.
42. McLennan, H. (1963) Synaptic Transmission, W. B. Saunders Co., Philadelphia, pp. 1-134.
43. Nakajima, T. (1991) Discovery of dopamine deficiency and the possibility of dopa therapy in Parkinsonism. In: Parkinson's Disease. From Clinical Aspects to Molecular Basis (T. Nagatsu, H. Narabayashi, and M. Yoshida M, eds.), Springer Verlag, Vienna, pp. 13-18.
44. Pletscher, A., Shore, P. A, and Brodie, B. B. (1955) Serotonin release as a possible mechanism of reserpine action. Science 122:374-375.
45. Pletscher, A., Shore, P. A., and Brodie, B. B. (1956) Serotonin as a mediator of reserpine action in brain. J. Pharmacol. Exp. Ther. 116:84-89.
46. Sacks, O. (1973) Awakenings, Gerald Duckworth, London, pp. 1-408.
47. Sano, I. (1959) Biochemical studies of aromatic monoamines in the brain. In: Japanese Medicine in 1959, The report on scientific meetings in the 15th General Assembly of the Japan Medical Congress, Vol. V, pp. 607-615.
48. Sano I. (2000) Biochemistry of extrapyramidal motor system. Shinkey Kenkyu no Shinpo (Adv. Neurol. Sci.) 5:42-48. English translation in: Parkinsonism and Related Disorders, Vol. 6 (2000), pp. 3-6.
49. Tedroff, J., Ekesbo, A., Sonesson, C., Waters, N., and Carlsson, A. (1999) Long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease. Neurology 53:1605-1606.
50. Vane, J. R., Wolstenholme, G. E. W., and O'Connor, M. (eds.) (1960) Ciba Foundation Symposium on Adrenergic Mechanisms, J. & A. Churchill Ltd., London, pp. 1-632.